Ribupatide has finished recruiting people for its three global late-stage weight-loss trials. That is progress toward an answer, not a new treatment available today. Kailera expects the first headline results in mid-2028. For someone already prescribed tirzepatide or semaglutide, this news doesn't change the treatment plan.
The drug remains investigational, meaning it is still being tested, and is not approved in any country. Its earlier results explain the interest. The larger studies have to show whether that promise holds up.
Ribupatide news: enrollment is complete, results are ahead
As of October 1, 2026, the day this article was written, Kailera's September 30 announcement confirms completed enrollment across KaiNETIC-1, KaiNETIC-2 and KaiNETIC-3. Their approximate counts add up to 4,900 participants at more than 200 sites across 11 countries.
Phase 3 means larger studies testing treatment effects and risks. Here, participants receive weekly study treatment for 76 weeks, with ribupatide doses up to 10 mg. Those are trial doses, not a prescribing schedule.
| Trial | Approximate enrollment | Who joined | Main question at week 76 |
|---|---|---|---|
| KaiNETIC-1 | 2,500 | Adults with obesity, or overweight with another health condition, without type 2 diabetes | Percentage change in weight |
| KaiNETIC-2 | 1,200 | Adults with overweight or obesity and type 2 diabetes | Weight change and A1c change |
| KaiNETIC-3 | 1,200 | Adults with BMI of at least 35, without type 2 diabetes | Weight change against placebo and semaglutide 2.4 mg |
BMI is a weight-to-height measure. A1c is a blood test reflecting average blood sugar over roughly three months. Placebo is an inactive comparison treatment.
“Enrollment complete” means the volunteers have joined. It doesn't mean they have finished treatment or that researchers know the outcome. Our guide to the phases of clinical trials explains the steps that remain.
Why ribupatide gets compared with tirzepatide
Ribupatide, also called HRS9531 or KAI-9531, came from Hengrui Pharma. In May 2024, Hengrui licensed development and commercial rights outside Greater China to Kailera, according to the announcement above.
Like tirzepatide, it activates receptors, the docking points on cells, for GLP-1 and GIP. These two gut hormones help govern appetite and blood sugar. That is what “dual agonist” means: one medicine switches on both signals.
The shared targets explain the comparison. They don't make the drugs interchangeable, or establish which works better for a particular person.
What the earlier HRS9531 phase 2 trial found
The earlier obesity study enrolled 249 Chinese adults without diabetes and followed them for 24 weeks. Results appeared as a conference abstract in Diabetes in 2024; the investigators' original poster provides the figures and analysis details.
Average weight loss was 5.4%, 13.4%, 14.0% and 16.8% across the 1, 3, 4.5 and 6 mg groups. Placebo participants lost 0.1%. The analysis included observed measurements after treatment stopped, rather than counting only people who stayed on the medicine.
At 6 mg, about 1 in 3 participants reported nausea: 32.7%, against 8.2% with placebo. Vomiting affected 28.6%, against 2.0%. Nobody stopped because of an event judged treatment-related; that doesn't mean nobody had side effects.
These are encouraging early findings from a specific population. A conference abstract and poster also provide less detail than a full trial paper.
Ribupatide vs tirzepatide: what a fair comparison needs
Tirzepatide's SURMOUNT-1 trial enrolled 2,539 adults without diabetes and followed them for 72 weeks. In Jastreboff and colleagues' NEJM paper from 2022, average weight loss ranged from 15.0% to 20.9% by dose, against 3.1% with placebo.
Those figures can't rank the drugs. The studies differed in size, duration, starting weight and population. Twenty-four weeks on ribupatide is not the same test as 72 weeks on tirzepatide.
KaiNETIC-3 should provide a more useful comparison with semaglutide because both medicines are tested within the same study. The semaglutide group is open-label, meaning participants know which medicine they receive. It still won't answer whether ribupatide beats tirzepatide.
Other experimental drugs targeting the same two signals include enicepatide and VK2735. Their separate headlines aren't substitutes for a direct comparison either.
What today's EASD injection-site data actually show
As of October 1, 2026, the day this article was written, Kailera's October 1 release reports a 51-person study presented at the European Association for the Study of Diabetes meeting in Milan. Each participant received single study doses in the abdomen, upper arm and thigh in separate periods.
Drug exposure, the amount reaching the blood over time, was similar across those sites. That supports further development of those injection locations. It doesn't establish equal weight loss by site or tell someone where to inject another medicine.
There is fresh published evidence too. As of October 1, 2026, the day this article was written, He and colleagues' paper, published September 20 in Diabetes, Obesity and Metabolism, reports early testing in 90 healthy Chinese participants. Its repeated-dose portion lasted four weeks. That adds human safety information, but cannot settle long-term risks.
What this news doesn't change for a prescription today
Ribupatide is not FDA-approved. As of October 1, 2026, the day this article was written, Hengrui's September 10 announcement reports acceptance of its diabetes marketing application in China. The same announcement says a separate application for long-term weight management in adults has been under review in China since September 2025. Acceptance starts review; it isn't permission to market the drug. The global trials remain a separate program.
Through Promise, tirzepatide and semaglutide are dispensed as compounded medications, which are different from an FDA-approved product: the formulations offered here are not FDA-approved. The FDA explains that it does not review compounded preparations for safety, effectiveness or quality before marketing.
These trial results do not establish outcomes for a pharmacy's compounded preparation.
A licensed provider may still prescribe a compounded formulation where appropriate; that decision is between you and your doctor. At Promise, a licensed provider reviews every request, and not everyone qualifies.
What to watch next, including oral ribupatide
The next meaningful global milestone is the first headline results, which Kailera expects in mid-2028. The useful details will include weight change, side effects and how many people stopped treatment. A results date is not a launch date.
As of October 1, 2026, the day this article was written, Kailera's September 30 release also places planned global phase 3 trials of daily oral ribupatide in the first half of 2027. The tablet is a separate development effort, not a pill available now.
After results, a marketing application still needs review. The FDA's explanation of drug review describes that separate decision. For now, the milestone is that the studies have their participants. The answers come later.
